2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Lung Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
5
Ovarian Neoplasms
5
Esophageal Neoplasms
5
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Retinoblastoma
2
Resectable Non-small Cell Lung Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Squamous-Cell Lung Cancer
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Retinal Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Lung Non-Small Cell Carcinoma
1
Recurrence
1
Psoriasis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Oropharyngeal Neoplasms
1
Nonsquamous Non-small Cell Lung Cancer
1
Non-Squamous Non-Small Cell Lung Cancer
1
NSCLC
1
Multiple Sclerosis
1
Melanoma
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Platinum Compounds
×
Clear all
NCT07340164
2026-04-20
TROY
Yonsei University
Phase 2
Recruiting
116 enrolled